Paper of the Day
Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age
Semaglutide, a weekly injected drug, is approved for obesity in teenagers and adults, but there has been little evidence on whether it helps younger children.
Why it matters A weekly obesity drug already used by teenagers and adults also lowers body-mass index substantially in children aged 6 to 11.
In this trial, 167 children aged 6 to 11 with obesity were randomly given weekly semaglutide or a dummy injection for two years, and all of them received advice on lifestyle changes. After 68 weeks, body-mass index had fallen by 13.5% on average with semaglutide and risen by 2.7% with the dummy injection. The difference was still large at two years. Side effects were reported in nearly all children in both groups, those on semaglutide and those on the dummy injection.
Buch et al., NEJM Current Issue, 16 November 2026. doi:10.1056/nejmoa2604058
Read the paper: Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age

















